0001104659-26-061213
SEC filingFennec reported its first quarterly net income and positive operating cash flow, driven by strong revenue growth and a favorable working capital swing — reflecting improved commercial execution and collection efficiency for PEDMARK®.
Revenue for Q1 FY2026 totaled $15.1 million, a 72.6% increase over $8.8 million in Q1 FY2025. This growth reflects continued commercial traction for PEDMARK®, particularly following Norgine’s 2025 launches in Germany and the U.K., with additional international launches expected throughout 2026. The year-over-year improvement aligns with the Company’s stated priority of ensuring seamless access for advocacy groups, payers, and providers — alongside patient and caregiver activation through disease education.
Operating income improved to a loss of $119.0 thousand, compared to a loss of $808.0 thousand in the prior-year quarter — a 85.3% improvement in magnitude. While still negative, this narrowing reflects scaling revenue against disciplined cost management. Net income shifted to $201.0 thousand, reversing last year’s $1.2 million loss. As noted in Management’s Discussion, this inflection was driven not only by top-line growth but also by a favorable swing in working capital — specifically, a significant decrease in accounts receivable in 2026 versus a build-up in 2025.
Net cash provided by operating activities was $2.4 million, a marked reversal from the $4.3 million outflow in Q1 FY2025. This shift underscores improved operational efficiency in collections and commercial execution. The Company’s investment policy — prioritizing preservation of principal, liquidity, and return on investment — remains unchanged and continues to guide how operating cash is deployed and preserved.
The Company maintains a conservative financial posture: no debt, no off-balance-sheet obligations, and an explicit investment strategy centered on capital preservation. Management has emphasized that policy risks stem primarily from the opportunity cost of this conservatism — not from credit or liquidity stress. With PEDMARQSI® now commercially available in multiple markets and further launches anticipated in 2026, the Company’s near-term financial performance remains closely tied to execution of its global commercial plan and continued progress on market access. Any potential label expansion would require additional clinical data and regulatory approvals — a reminder that long-term growth remains contingent on both commercial and clinical milestones.